Seattle Genetics Inc. said it will be getting $12 million, in addition to an option for cost and profit sharing on a third program using the ADC technology, as part of an expanded partnership with Astellas unit, Agensys Inc. In turn, Agensys will receive exclusive rights to technology aimed at developing cancer treatments.
Partners since 2007, the companies are focusing on developing cancer treatments. If all the additional ADC programs are successful, Seattle Genetics will be eligible to receive up to $250 million in development milestones and $100 million in sales milestones.
In morning trading, shares of Seattle Genetics rose 10 cents to $9.40.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
